Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol Ther
Autors principals: Hicks, JK, Bishop, JR, Sangkuhl, K, Müller, DJ, Ji, Y, Leckband, SG, Leeder, JS, Graham, RL, Chiulli, DL, LLerena, A, Skaar, TC, Scott, SA, Stingl, JC, Klein, TE, Caudle, KE, Gaedigk, A
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
CPIC Guidelines
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512908/
https://ncbi.nlm.nih.gov/pubmed/25974703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.147
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars